Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × NSCLC × Radiosurgery × Clear all

Phase

Status

Recruiting 2 Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 17 Carcinoma, Non-Small-Cell Lung 15 Brain Neoplasms 11 Pancreatic Neoplasms 9 Neoplasm Metastasis 9 Carcinoma, Hepatocellular 9 Breast Neoplasms 9 Neoplasms 4 Recurrence 3 Lung Neoplasms 3 Neuroma, Acoustic 2 Head and Neck Neoplasms 2 Glioblastoma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Urinary Bladder Neoplasms 1 Stage IA - IB Non Small Cell Lung Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 Spine Metastasis 1 Spinal Neoplasms 1 Spinal Bone Metastases 1 Solid Tumor 1 Sarcoma 1 Rare Diseases 1 Radiotherapy 1 Prostate Cancer Metastatic 1 Prostate Adenocarcinoma 1 Pituitary Neoplasms 1 Patients With Advanced Metastatic Colorectal Cancer 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Gefitinib 5 icotinib 4 apatinib 3 anlotinib 3 Pemetrexed 3 Erlotinib Hydrochloride 3 Docetaxel 3 osimertinib 2 dacomitinib 2 camrelizumab 2 aflutinib 2 Thalidomide 2 Drug Therapy 2 Carboplatin 2 spartalizumab 1 pembrolizumab 1 envafolimab 1 Vinorelbine 1 Tyrosine Kinase Inhibitors 1 S 1 (combination) 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Cisplatin 1 Bevacizumab 1 Axitinib 1 Aspirin 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03256981 2023-12-26

HALT

Institute of Cancer Research, United Kingdom

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡